Tango Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 5.43 million compared to USD 6.41 million a year ago. Net loss was USD 30.76 million compared to USD 29.06 million a year ago.

Basic loss per share from continuing operations was USD 0.32 compared to USD 0.33 a year ago.